Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the potential importance of early intervention in pediatric patients, and how addressing AD at an early stage may stop the clock on associated systemic comorbidities in the long term.
Practical Considerations in Older Patients with AD
Dermatology
This video from the March 2024 ADVENT AD symposium features Dr. Katrina Abuabara presenting on practical considerations in older patients with AD. Dr. Abuabara elaborates on several unique challenges faced by older adult patients with AD, including differential diagnoses and age-dependent clinical factors and decisions relevant to their disease management. She goes on to discuss the concept of “inflamm-aging” as it relates to systemic inflammatory markers and associated comorbidities in older adult patients, followed by a brief panel discussion.
The Cumulative Disease Burden of AD in Adult Patients
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Eric Simpson discusses the array of allergic and non-allergic comorbidities that may impact adult patients with AD and how the cumulative burden of these comorbidities contributes to reduced quality of life. He goes on to discuss the potential for addressing the multimorbidities related to AD through early intervention before they have the opportunity to develop or progress.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.